Expression of P53 and Its Mechanism in Prostate Cancer

Overview

Journal Oncol Lett

Specialty Oncology

Date 2018 Jun 22

PMID 29928424

Citations 5

Authors

Jiukai Wan

Jun Zhang

Junqiang Zhang

Affiliations

Soon will be listed here.

Abstract

The present study aimed to investigate the expression of tumor protein p53 (p53), and its mechanism of function, in prostate cancer (PC). Small interfering RNA (siRNA) was used to interfere with p53 expression in the PC cell line, DU145. Cell viability and p53 expression were analyzed using cell counting kit-8 (CCK-8) and western blotting. The effects of p53 expression on the proliferation, migration and adhesion abilities of PC cells were analyzed using Cell Counting kit-8, Transwell and adhesion assays. Changes in cell proliferation, migration and adhesion ability were observed following treatment with extracellular signal-regulated kinase (ERK) inhibitor, PD184352, and janus kinase (JNK) inhibitor, SP60012. The expression level of p53 declined 24 h after siRNA transfection (P<0.05). Furthermore, JNK and ERK, downstream proteins of the focal adhesion kinase (FAK)-Src proto-oncogene, non-receptor tyrosine kinase (Src) signaling pathway, were activated. These effects were associated with reduced proliferation, migration and adhesion abilities of PC cells compared with untransfected control cells (P<0.05). PD184352 and SP600125 treatments also resulted in reduced proliferation, migration and adhesion abilities of PC cells (P<0.05). In conclusion, PC cells exhibited low p53 expression, and the proliferation, migration and adhesion abilities of PC cells were promoted by inhibiting the activation of JNK and ERK. Together, these results suggest that p53 has potential as a therapeutic target in PC.

Citing Articles

Exosomal AHSG in ovarian cancer ascites inhibits malignant progression of ovarian cancer by p53/FAK/Src signaling.

Xie G, Zhang Y, Ma J, Guo X, Xu J, Chen L Transl Cancer Res. 2024; 13(10):5365-5380.

PMID: 39525039 PMC: 11543047. DOI: 10.21037/tcr-24-789.

Androgen receptor binding sites enabling genetic prediction of mortality due to prostate cancer in cancer-free subjects.

Ito S, Liu X, Ishikawa Y, Conti D, Otomo N, Kote-Jarai Z Nat Commun. 2023; 14(1):4863.

PMID: 37612283 PMC: 10447511. DOI: 10.1038/s41467-023-39858-8.

A comparative assessment of and genes expression in the sperm samples obtained from males with normozoospermia and asthenospermia: A case-control study.

Alizadeh A, Mirzaahmadi S, Asaadi Tehrani G, Jabbara N Int J Reprod Biomed. 2023; 20(12):1019-1028.

PMID: 36819206 PMC: 9928977. DOI: 10.18502/ijrm.v20i12.12563.

Therapeutic Potential of Marine Peptides in Prostate Cancer: Mechanistic Insights.

Ahmed S, Alam W, Jeandet P, Aschner M, Alsharif K, Saso L Mar Drugs. 2022; 20(8).

PMID: 35892934 PMC: 9330892. DOI: 10.3390/md20080466.

Transcription factor p53-mediated activation of miR-519d-3p and downregulation of E2F1 attenuates prostate cancer growth and metastasis.

Zhang D, Yang X, Luo Q, Xue L, Chong T Cancer Gene Ther. 2021; 29(7):1001-1011.

PMID: 34799723 DOI: 10.1038/s41417-021-00405-6.

References

Ha U, Bae W, Kim S, Yoon B, Hong S, Lee J . Anthocyanin induces apoptosis of DU-145 cells in vitro and inhibits xenograft growth of prostate cancer. Yonsei Med J. 2014; 56(1):16-23. PMC: 4276751. DOI: 10.3349/ymj.2015.56.1.16. View

Singh R, Patel K, Patel P . "p53 mutation spectrum and its role in prognosis of oral cancer patients: A study from Gujarat, West India". Mutat Res. 2015; 783:15-26. DOI: 10.1016/j.mrfmmm.2015.12.001. View

Jiang T, Zhou C, Gu J, Liu Y, Zhao L, Li W . Enhanced therapeutic effect of cisplatin on the prostate cancer in tumor-bearing mice by transfecting the attenuated Salmonella carrying a plasmid co-expressing p53 gene and mdm2 siRNA. Cancer Lett. 2013; 337(1):133-42. DOI: 10.1016/j.canlet.2013.05.028. View

Zhang H, Zhang S, He H, Zhang C, Yu D, Shao R . Downregulation of G3BPs inhibits the growth, migration and invasion of human lung carcinoma H1299 cells by suppressing the Src/FAK-associated signaling pathway. Cancer Gene Ther. 2013; 20(11):622-9. DOI: 10.1038/cgt.2013.62. View

Alva A, Hussain M . Optimal pharmacotherapeutic management of hormone-sensitive metastatic prostate cancer. Drugs. 2013; 73(14):1517-24. DOI: 10.1007/s40265-013-0106-3. View

Thomsen F, Folkvaljon Y, Garmo H, Robinson D, Loeb S, Ingvar C . Risk of malignant melanoma in men with prostate cancer: Nationwide, population-based cohort study. Int J Cancer. 2015; 138(9):2154-60. DOI: 10.1002/ijc.29961. View

Cai S, Han K . Research on expression and importance of p53, p16 and VEGF-C in cervical cancer. J Gynecol Obstet Biol Reprod (Paris). 2014; 44(7):639-45. DOI: 10.1016/j.jgyn.2014.07.012. View

Wang Y, Zhang Y, Kong C, Zhang Z, Zhu Y . Loss of P53 facilitates invasion and metastasis of prostate cancer cells. Mol Cell Biochem. 2013; 384(1-2):121-7. DOI: 10.1007/s11010-013-1789-1. View

Thakur R, Trivedi R, Rastogi N, Singh M, Mishra D . Inhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer. Sci Rep. 2015; 5:10194. PMC: 4431480. DOI: 10.1038/srep10194. View

10.

Henriquez-Hernandez L, Valenciano A, Foro-Arnalot P, Alvarez-Cubero M, Cozar J, Suarez-Novo J . Genetic variations in genes involved in testosterone metabolism are associated with prostate cancer progression: A Spanish multicenter study. Urol Oncol. 2015; 33(7):331.e1-7. DOI: 10.1016/j.urolonc.2015.04.003. View

11.

Teh B, Ishiyama H . Hypofractionated radiotherapy for prostate cancer. Lancet Oncol. 2011; 13(1):5-6. DOI: 10.1016/S1470-2045(11)70347-3. View

12.

Meek D . Regulation of the p53 response and its relationship to cancer. Biochem J. 2015; 469(3):325-46. DOI: 10.1042/BJ20150517. View

13.

Sivonova M, Vilckova M, Kliment J, Mahmood S, Jurecekova J, Dusenkova S . Association of and polymorphisms with prostate cancer. Biomed Rep. 2015; 3(5):707-714. PMC: 4576486. DOI: 10.3892/br.2015.496. View

14.

Gu J, Wang B, Liu Y, Zhong L, Tang Y, Guo H . Murine double minute 2 siRNA and wild-type p53 gene therapy interact positively with zinc on prostate tumours in vitro and in vivo. Eur J Cancer. 2014; 50(6):1184-94. DOI: 10.1016/j.ejca.2013.12.027. View

15.

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

16.

Nande R, Greco A, Gossman M, Lopez J, Claudio L, Salvatore M . Microbubble-assisted p53, RB, and p130 gene transfer in combination with radiation therapy in prostate cancer. Curr Gene Ther. 2013; 13(3):163-74. DOI: 10.2174/1566523211313030001. View